Centro De Oftalmologia Barraquer S.A.

The Centro De Oftalmologia Barraquer S.A. focuses on advancing treatments for Age-Related Macular Degeneration, addressing both dry and wet forms as well as geographic atrophy.

• Testing novel anti‑VEGF agents to improve visual outcomes in neovascular AMD
• Evaluating sustained‑release port delivery systems for long‑term therapy
• Investigating complement pathway blockers to reduce geographic atrophy progression
• Assessing gene‑therapy approaches for durable vision preservation

These studies aim to enhance efficacy, safety, and patient convenience while preserving sight.

Clinical trials at the Barcelona site target Diabetic Macular Edema, seeking better control of fluid accumulation and visual loss.

• Comparing new intravitreal formulations to standard anti‑VEGF therapy
• Measuring changes in best‑corrected visual acuity using the ETDRS chart
• Monitoring intraocular pressure for safety profiling
• Exploring adjunctive topical treatments to reduce retinal swelling

The goal is to identify therapies that offer superior effectiveness with comparable safety.

Researchers evaluate innovative options for managing dry eye disease and associated meibomian gland dysfunction, a common ocular surface condition.

• Assessing symptom improvement with lid hygiene and artificial tears
• Testing a medical device combined with low‑dose steroids for relief
• Analyzing tear cytokine levels to understand inflammatory changes
• Determining safety by tracking ocular pressure fluctuations

These trials strive to provide patients with faster symptom relief and better quality of life.

The center conducts studies on persistent corneal epithelial defects, focusing on accelerated re‑epithelialization and wound stability.

• Comparing an ophthalmic gel to its vehicle for healing speed
• Using digital fluorescein imaging to quantify defect closure
• Evaluating durability of re‑epithelialization over a 28‑day period
• Monitoring adverse events to ensure tolerability

The research aims to reduce treatment burden and prevent vision‑threatening complications.

Ongoing trials at Barraquer explore therapies for Thyroid Eye Disease, an autoimmune condition affecting orbital tissues.

• Evaluating a novel biologic for reduction of orbital inflammation
• Measuring efficacy against placebo in a multicenter setting
• Tracking safety through systemic and ocular adverse‑event reporting
• Assessing improvements in eye bulging and visual function

These studies seek to offer patients a targeted, disease‑modifying treatment option.

Specialized investigations address polypoidal choroidal vasculopathy and other neovascular eye diseases, aiming to refine therapeutic strategies.

• Testing faricimab efficacy in patients with PCV
• Measuring visual acuity outcomes in a Caucasian cohort
• Comparing injection intervals to reduce treatment frequency
• Monitoring lesion regression through imaging biomarkers

The purpose is to improve disease control while lessening the treatment burden for patients.